Final Results of the Phase I/II Clinical Study of BST-236 in Acute Leukemia Patients will be Presented at the 2017 Annual ASH Meeting

AIRPORT CITY, Israel, Dec. 4, 2017 /PRNewswire/ -- BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, is pleased to announce the results of a Phase I/II clinical study of BST-236 in acute leukemia patients have been selected by the ASH Program Committee for an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition (December 9-12, 2017) in Atlanta, GA.

The Phase I/II clinical trial was a multi-center, dose-escalation, open-label, single arm study to evaluate the safety and efficacy of BST-236 as a single agent in adults with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). The study enrolled 26 patients, either relapsed/refractory or newly-diagnosed unfit for standard therapy.

BST-236 is a novel cytarabine pro-drug, enabling safe delivery of high cytarabine doses to leukemia patients. Cytarabine is the backbone of current AML treatment; however, it is highly toxic and associated with severe side effects, especially in older populations. Therefore, while the median age at AML diagnosis is almost 70 years, cytarabine doses are significantly attenuated for older patients and for patients with liver and kidney dysfunction. BST-236 enables the delivery of cytarabine to leukemia cells with low systemic exposure to the free drug. Inside the leukemia blasts, cytarabine is released and triggers cell death, while normal tissues are relatively spared. As such, BST-236 may serve as an ideal therapy for leukemia, particularly for delivering high doses of cytarabine to medically unfit or older adults who otherwise may mainly be treated with reduced intensity or supportive therapy with poor outcomes.

The final results of the BST-236 Phase I/II study in acute leukemia patients will be presented at the 59^th ASH Annual Meeting and Exposition in Atlanta by Dr. Tsila Zuckerman, the Head of the Bone Marrow Transplantation Unit at Rambam Healthcare Campus, Technion, Israel:

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

• Date & Time: Monday, December 11, 2017, 7:15 PM
• Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML
• Abstract Number: 893
• Location: Building B, Level 5, Murphy BR 1-2 (Georgia World Congress Center)

About BioSight Ltd.:

BioSight is a private Israeli clinical-stage pharmaceutical development company, founded by Dr. Stela Gengrinovitch and headed by Dr. Ruth Ben Yakar.

BioSight focuses on the development of novel caner-targeted chemotherapy pro-drugs. BioSight's lead proprietary product BST-236 is in clinical development stages for treatment of acute leukemia.

Contact:
Dr. Ruth Ben Yakar, CEO
[email protected]

SOURCE BioSight, Ltd

Related Links

https://www.biosight-pharma.com